This video reviews the treatment of mantle cell lymphoma cases that do not fit the typical mold.
In this video, Peter Martin, MD, of Weill Cornell Medicine in New York, discusses the treatment of mantle cell lymphoma cases that do not fit the typical mold.
Martin gave a presentation on this topic during an education session at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9–12 in Atlanta.
Low Rates of Chronic Graft-Versus-Host Disease With Ruxolitinib Maintenance Following Allogeneic HCT
June 2nd 2025Researchers conducted a prospective, multicenter phase II clinical trial demonstrating that prolonged administration of ruxolitinib after allogeneic HCT is associated with notably low rates of cGVHD.